Annual direct healthcare costs for chronic hepatitis C escalate sharply with disease progression, from roughly $4,483 per patient per month for chronic infection to $19,021 for hepatocellular carcinoma and $27,836 at the liver transplant stage. An estimated 2.4 to 4 million U.S. adults have current HCV infection, and it remains the most commonly reported chronic bloodborne infection in the country. Against that gradient, a pangenotypic direct-acting antiviral regimen of 8 to 12 weeks achieves cure rates exceeding 95% across all genotypes, which makes the timing of treatment, not its availability, the principal utilization question.
AAVBC's Hepatitis C Medication Utilization Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering FDA-approved DAA indications, contraindications and precautions, pretreatment laboratory checks that stratify PCP-managed versus referral pathways, drug interaction management, regimen selection and duration, on-treatment monitoring and SVR12 confirmation, retreatment after prior failure, cost-smart prescribing including authorized generics and the Inflation Reduction Act out-of-pocket cap, and a closed-loop pathway with patient-centered conversation guidance. Grounded in the AASLD simplified treatment algorithm and current peer-reviewed literature, this guide supports consistent, individualized clinical decision-making, helping care teams move eligible patients to cure before disease progression compounds cost, with the clarity and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of hepatitis C medication — moving far beyond quick-reference essentials. These guides provide an integrated review of financial implications, decision frameworks, target conditions, risk stratifications, document requirements as well as billing and coding considerations. The Deep-Dives combine evidence-informed clinical guidance with practical operational tools to support a deeper understanding of anticoagulation therapies, and provide care teams with the necessary strategies to thrive within a value-based framework.
Annual direct healthcare costs for chronic hepatitis C escalate sharply with disease progression, from roughly $4,483 per patient per month for chronic infection to $19,021 for hepatocellular carcinoma and $27,836 at the liver transplant stage. An estimated 2.4 to 4 million U.S. adults have current HCV infection, and it remains the most commonly reported chronic bloodborne infection in the country. Against that gradient, a pangenotypic direct-acting antiviral regimen of 8 to 12 weeks achieves cure rates exceeding 95% across all genotypes, which makes the timing of treatment, not its availability, the principal utilization question.
AAVBC's Hepatitis C Medication Utilization Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering FDA-approved DAA indications, contraindications and precautions, pretreatment laboratory checks that stratify PCP-managed versus referral pathways, drug interaction management, regimen selection and duration, on-treatment monitoring and SVR12 confirmation, retreatment after prior failure, cost-smart prescribing including authorized generics and the Inflation Reduction Act out-of-pocket cap, and a closed-loop pathway with patient-centered conversation guidance. Grounded in the AASLD simplified treatment algorithm and current peer-reviewed literature, this guide supports consistent, individualized clinical decision-making, helping care teams move eligible patients to cure before disease progression compounds cost, with the clarity and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of hepatitis C medication — moving far beyond quick-reference essentials. These guides provide an integrated review of financial implications, decision frameworks, target conditions, risk stratifications, document requirements as well as billing and coding considerations. The Deep-Dives combine evidence-informed clinical guidance with practical operational tools to support a deeper understanding of anticoagulation therapies, and provide care teams with the necessary strategies to thrive within a value-based framework.
